CLARUS THERAPEUTICS HLDNGS I's ticker is and the CUSIP is 18271L107. A total of 2 filers reported holding CLARUS THERAPEUTICS HLDNGS I in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $12,000 | – | 32,525 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bracebridge Capital, LLC | 2,002,495 | $4,866,000 | 0.30% |
| Powell Investment Advisors, LLC | 64,000 | $156,000 | 0.09% |
| ARMISTICE CAPITAL, LLC | 1,929,876 | $4,690,000 | 0.08% |
| TUDOR INVESTMENT CORP ET AL | 18,148 | $44,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 12,923 | $31,000 | 0.00% |
| Verition Fund Management LLC | 30,000 | $73,000 | 0.00% |
| Schonfeld Strategic Advisors LLC | 20,800 | $51,000 | 0.00% |
| WELLS FARGO & COMPANY/MN | 25 | $0 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| MORGAN STANLEY | 2 | $0 | 0.00% |